---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-113480"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T07:10:41.965353+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theriva shareholders approve 8.9x stock plan share increase and 25x authorized share increase.

## Summary
- Stockholders approved Amendment No. 2 to the 2020 Stock Incentive Plan, increasing the share reserve from 280,000 to 2,500,000 shares.
- Non-employee director annual grant limit raised from 40,000 to 250,000 shares under the amended plan.
- Certificate of Change filed to increase authorized common shares from 14,000,000 to 350,000,000, effective November 1, 2024.
- All four director nominees elected; BDO USA, P.C. ratified as independent auditor for FY2024.
- Shareholders also approved the adjournment proposal, but it was not needed as quorum was present.

## SEC filing metadata
- accession: 0001104659-24-113480
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924113480/0001104659-24-113480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924113480/tm2427299d1d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-113480
- JSON: https://secwatch.observer/filing/0001104659-24-113480.json
- Plain text: https://secwatch.observer/filing/0001104659-24-113480.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.